Dexrazoxane Prevents Anthracycline-Related Cardiotoxicity in Childhood AML

New data from researchers at the Children’s Hospital of Philadelphia (CHOP) suggests use of dexrazoxane could provide some much-needed cardiovascular protection to pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML).

Read more: https://www.mdmag.com/medical-news/dexrazoxane-prevents-anthracyclinerelated-cardiotoxicity-in-childhood-aml